Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

CD4(+)Foxp3(+) regulatory T cell therapy in transplantation.

Tang Q, Bluestone JA, Kang SM.

J Mol Cell Biol. 2012 Feb;4(1):11-21. doi: 10.1093/jmcb/mjr047. Epub 2011 Dec 14. Review.

2.

Double negative regulatory T cells in transplantation and autoimmunity: recent progress and future directions.

Juvet SC, Zhang L.

J Mol Cell Biol. 2012 Feb;4(1):48-58. doi: 10.1093/jmcb/mjr043. Review.

3.

Induced Foxp3(+) regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases?

Lan Q, Fan H, Quesniaux V, Ryffel B, Liu Z, Zheng SG.

J Mol Cell Biol. 2012 Feb;4(1):22-8. doi: 10.1093/jmcb/mjr039. Epub 2011 Nov 22. Review.

4.

Impact of immunosuppressants on the therapeutic efficacy of in vitro-expanded CD4+CD25+Foxp3+ regulatory T cells in allotransplantation.

Lim DG, Koo SK, Park YH, Kim Y, Kim HM, Park CS, Kim SC, Han DJ.

Transplantation. 2010 Apr 27;89(8):928-36. doi: 10.1097/TP.0b013e3181d3c9d4.

PMID:
20305583
5.

CD4+ T-regulatory cells: toward therapy for human diseases.

Allan SE, Broady R, Gregori S, Himmel ME, Locke N, Roncarolo MG, Bacchetta R, Levings MK.

Immunol Rev. 2008 Jun;223:391-421. doi: 10.1111/j.1600-065X.2008.00634.x. Review.

PMID:
18613849
6.
7.

Dendritic cells expand antigen-specific Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity.

Yamazaki S, Inaba K, Tarbell KV, Steinman RM.

Immunol Rev. 2006 Aug;212:314-29. Review.

PMID:
16903923
8.

FOXP3+ regulatory T cells: from suppression of rejection to induction of renal allograft tolerance.

Dummer CD, Carpio VN, Gonçalves LF, Manfro RC, Veronese FV.

Transpl Immunol. 2012 Jan;26(1):1-10. doi: 10.1016/j.trim.2011.08.009. Epub 2011 Sep 13. Review.

PMID:
21939765
9.

Role of naturally arising regulatory T cells in hematopoietic cell transplantation.

Nguyen VH, Zeiser R, Negrin RS.

Biol Blood Marrow Transplant. 2006 Oct;12(10):995-1009. Review.

10.

Comparative analysis of dendritic cells and anti-CD3/CD28 expanded regulatory T cells for application in transplantation.

Zeng M, Guinet E, Nouri-Shirazi M.

Transpl Immunol. 2009 Dec;22(1-2):82-92. doi: 10.1016/j.trim.2009.07.004. Epub 2009 Jul 25.

PMID:
19635560
11.

Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction.

Yamazaki S, Patel M, Harper A, Bonito A, Fukuyama H, Pack M, Tarbell KV, Talmor M, Ravetch JV, Inaba K, Steinman RM.

Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2758-63. Epub 2006 Feb 10.

12.

Therapeutic potential of induced and natural FoxP3(+) regulatory T cells for the treatment of Graft-versus-host disease.

Prinz I, Koenecke C.

Arch Immunol Ther Exp (Warsz). 2012 Jun;60(3):183-90. doi: 10.1007/s00005-012-0172-3. Epub 2012 Apr 5. Review.

PMID:
22476537
13.

Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD.

Koenecke C, Czeloth N, Bubke A, Schmitz S, Kissenpfennig A, Malissen B, Huehn J, Ganser A, Förster R, Prinz I.

Eur J Immunol. 2009 Nov;39(11):3091-6. doi: 10.1002/eji.200939432.

14.

CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice.

Miao CH, Harmeling BR, Ziegler SF, Yen BC, Torgerson T, Chen L, Yau RJ, Peng B, Thompson AR, Ochs HD, Rawlings DJ.

Blood. 2009 Nov 5;114(19):4034-44. doi: 10.1182/blood-2009-06-228155. Epub 2009 Aug 27.

15.

Induction of Foxp3-expressing regulatory T-cells by donor blood transfusion is required for tolerance to rat liver allografts.

Abe Y, Urakami H, Ostanin D, Zibari G, Hayashida T, Kitagawa Y, Grisham MB.

PLoS One. 2009 Nov 23;4(11):e7840. doi: 10.1371/journal.pone.0007840.

16.

Human regulatory T cells: role in autoimmune disease and therapeutic opportunities.

Brusko TM, Putnam AL, Bluestone JA.

Immunol Rev. 2008 Jun;223:371-90. doi: 10.1111/j.1600-065X.2008.00637.x. Review. Erratum in: Immunol Rev. 2009 May;229(1):388.

PMID:
18613848
17.

Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models.

Duramad O, Laysang A, Li J, Ishii Y, Namikawa R.

Biol Blood Marrow Transplant. 2011 Aug;17(8):1154-68. doi: 10.1016/j.bbmt.2010.11.022. Epub 2010 Dec 8.

18.

Induction of alloantigen-specific human T regulatory cells by vasoactive intestinal peptide.

Pozo D, Anderson P, Gonzalez-Rey E.

J Immunol. 2009 Oct 1;183(7):4346-59. doi: 10.4049/jimmunol.0900400. Epub 2009 Sep 4.

19.

Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model.

Yang J, Fan H, Hao J, Ren Y, Chen L, Li G, Xie R, Yang Y, Qian K, Liu M.

Transfusion. 2012 Jun;52(6):1333-47. doi: 10.1111/j.1537-2995.2011.03448.x. Epub 2011 Nov 21.

PMID:
22098312
20.
Items per page

Supplemental Content

Write to the Help Desk